The six
- 11,591,217; Antipathogenic Devices and Methods Thereof
- 11,672,252; Antifungal Composites and Methods Thereof
- 11,738,122; Antibacterial Biomedical Implants and Associated Materials, Apparatus, and Methods
- 11,844,344; Systems and Methods for Rapid Inactivation of SARS-COV-2 by Silicon Nitride and Aluminum Nitride
- 11,850,214; Antiviral Compositions and Devices and Methods of Use Thereof
- 11,857,001; Antipathogenic Face Mask
The significance of the six mentioned patents lies in their innovative approaches towards utilizing silicon nitride (Si3N4) in a wide range of antipathogenic solutions. The surface antipathogenic properties of silicon nitride have been published extensively in the peer literature by
The first two patents (US Patent Nos. 11,591,217 and 11,672,252) cover slurries and composites of silicon nitride with polymethyl methacrylate (PMMA) for use in combating fungal infections in plants and preventing fungal colonization of medical implants - including specific applications in dentistry. The third patent (US Patent No. 11,738,122) describes implants comprised of polymeric and titanium materials coated with SiYAlON (a subclass of silicon nitride materials) as well as implants made from composites of SiYAlON and polymers like polyetheretherketone (PEEK) as candidates for reducing infection burden in biomedical applications. (These coating and composite technologies are the foundation for recent and ongoing
The Company announced it has also received three foreign patents on its proprietary technologies in 2023.
“These patent grants and pending patent applications reflect SINTX’s commitment to protecting the intellectual property that has been created by the
###
About
For more information on
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including, but not limited to, statements regarding SINTX’s ability to effectively develop a range of innovative applications of our silicon nitride formulations, SINTX’s ability to commercialize its technologies and broaden the applications that benefit from silicon nitride, and other statements that are not based on historical fact. Such forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from current expectations. Risks and uncertainties that may cause such differences include, among other things: SINTX’s products may not prove to be as effective as other products currently being commercialized or to be commercialized in the future by competitors; risks inherent in manufacturing and scaling up to commercial quantities while maintaining quality controls and qualification standards; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of SINTX’s products once commercialized; risks related to manufacturing products and market acceptance volatility in the price of SINTX’s common stock; SINTX’s ability to raise funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the
Business and Media Inquiries for
801.839.3502
IR@sintx.com
Source:
2024 GlobeNewswire, Inc., source